Monica Armida
Overview
Explore the profile of Monica Armida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Potenza R, Armida M, Popoli P
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38339026
Amyotrophic lateral sclerosis (ALS) is a rare progressive motor neuron disease that, due to its high complexity, still lacks effective treatments. Development of a new drug is a highly costly...
2.
Butera A, De Simone R, Potenza R, Sanchez M, Armida M, Campanile D, et al.
Brain Behav Immun
. 2023 Oct;
115:89-100.
PMID: 37793488
To clarify the role of gut mucosal immunity in ASD, we evaluated, in the early-life immune activation (EIA) mouse model, the effects of administration of a monoclonal antibody directed against...
3.
Orienti I, Armida M, Dobrowolny G, Pepponi R, Sollazzini G, Pezzola A, et al.
Neuroscience
. 2021 Aug;
473:1-12.
PMID: 34363869
Amyotrophic lateral sclerosis (ALS) is the most frequent motor neuron disease for which effective treatment options are still lacking. ALS occurs in sporadic and familial forms which are clinically indistinguishable;...
4.
Ferrante A, Boussadia Z, Borreca A, Mallozzi C, Pedini G, Pacini L, et al.
Transl Psychiatry
. 2021 Feb;
11(1):112.
PMID: 33547274
In fragile X syndrome (FXS) the lack of the fragile X mental retardation protein (FMRP) leads to exacerbated signaling through the metabotropic glutamate receptors 5 (mGlu5Rs). The adenosine A receptors...
5.
De Simone R, Butera A, Armida M, Pezzola A, Boirivant M, Potenza R, et al.
Neuroscience
. 2020 Apr;
435:22-32.
PMID: 32229233
Autism Spectrum Disorders (ASD) are neurodevelopmental disorders characterized by social communication deficits and repetitive/stereotyped behaviours. We evaluated the effects of a chronic treatment with the immunomodulator drug Fingolimod (FTY720 -...
6.
Armida M, Matteucci A, Pezzola A, Baqi Y, Muller C, Popoli P, et al.
Neurochem Res
. 2019 Feb;
44(5):1037-1042.
PMID: 30756215
Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system...
7.
Domenici M, Chiodi V, Averna M, Armida M, Pezzola A, Pepponi R, et al.
Purinergic Signal
. 2018 May;
14(3):235-243.
PMID: 29770921
The A adenosine receptor (AR) is widely distributed on different cellular types in the brain, where it exerts a broad spectrum of pathophysiological functions, and for which a role in...
8.
Ferrante A, Pezzola A, Matteucci A, Di Biase A, Attorri L, Armida M, et al.
Neurobiol Dis
. 2017 Oct;
110:1-11.
PMID: 29079454
Niemann-Pick C is a fatal neurovisceral disorder caused, in 95% of cases, by mutation of NPC1 gene. Therapeutic options are extremely limited and new "druggable" targets are highly warranted. We...
9.
Potenza R, De Simone R, Armida M, Mazziotti V, Pezzola A, Popoli P, et al.
Neurotherapeutics
. 2016 Jul;
13(4):918-927.
PMID: 27456702
Fingolimod phosphate (FTY720), the first approved oral therapy for multiple sclerosis, primarily acts as an immunomodulator. Its concomitant effects in the central nervous system, however, indicate a potentially broader spectrum...
10.
Tartaglione A, Armida M, Potenza R, Pezzola A, Popoli P, Calamandrei G
Behav Brain Res
. 2016 Jul;
313:53-57.
PMID: 27374158
In the study of neurodegenerative diseases, rodent models provide experimentally accessible systems to study multiple pathogenetic aspects. The identification of early and robust behavioural changes is crucial to monitoring disease...